Biosimilars and Generics Drive Growth

Sandoz has reported robust financial results for the third quarter and nine months of 2024, with notable growth in both biosimilars and generics. For Q3, the company achieved net sales of USD 2.6 billion, a 12% increase in constant currencies. Over the first nine months, Sandoz reported net sales of USD 7.6 billion, up 9% in constant currencies.

CEO Richard Saynor highlighted the success of recent biosimilars launches, including Pyzchiva® and Enzeevu™ in the US, and strong performance from Hyrimoz® in the US market. The company also noted significant acceleration in generics sales, particularly in Europe.

Sandoz raised its sales growth guidance to a high-single-digit percentage in constant currencies and confirmed its core EBITDA margin guidance of around 20%. The company remains committed to its transformation efforts, continuing to simplify its operations and leverage a favorable product mix to enhance margins.